Skip to content

Advertisement

Sections

Page 3 of 35

  1. Content type: Research article

    Mismatch Repair Deficiency (MMR-D)-related tumors are highly immunogenic and constitute ideal vaccination targets. In a proof-of-concept study delayed tumorigenesis and prolonged survival has been shown in a c...

    Authors: Claudia Maletzki, Leonie Wiegele, Ingy Nassar, Jan Stenzel and Christian Junghanss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:8

    Published on:

  2. Content type: Research article

    High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to engineer potent T cells for therapeutic treatment of cancer patients. However, discovery of suitable therapeutic TCR genes is hamp...

    Authors: Junko Matsuzaki, Takemasa Tsuji, Thinle Chodon, Courtney Ryan, Richard C. Koya and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:7

    Published on:

  3. Content type: Review

    Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer. In particular, recombinant vaccinia vir...

    Authors: Zong Sheng Guo, Binfeng Lu, Zongbi Guo, Esther Giehl, Mathilde Feist, Enyong Dai, Weilin Liu, Walter J. Storkus, Yukai He, Zuqiang Liu and David L. Bartlett

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:6

    Published on:

  4. Content type: Research article

    Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonis...

    Authors: Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig and Manuel Schmidt

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:5

    Published on:

  5. Content type: Case report

    With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments ...

    Authors: Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe and Frances A. Collichio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:4

    Published on:

  6. Content type: Research article

    Thyroid cancer and thyroid autoimmunity are considered opposite extremes of immune-responses. However, several studies have suggested that thyroid cancer coexists with autoimmune thyroid diseases like Hashimot...

    Authors: Shahnawaz Imam, Pervaiz Dar, Rodis Paparodis, Khalil Almotah, Ahmed Al-Khudhair, Syed Abdul-Moiz Hasan, Nancy Salim and Juan Carlos Jaume

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:3

    Published on:

  7. Content type: Short report

    The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the ef...

    Authors: Omar Mamlouk, Umut Selamet, Shana Machado, Maen Abdelrahim, William F. Glass, Amanda Tchakarov, Lillian Gaber, Amit Lahoti, Biruh Workeneh, Sheldon Chen, Jamie Lin, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Nizar Tannir…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:2

    Published on:

  8. Content type: Case report

    Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being tre...

    Authors: Christopher C. Frohne, Ernesto M. Llano, Ashley Perkovic, Russell D. Cohen and Jason J. Luke

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:1

    Published on:

  9. Content type: Research article

    Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations. The prognosis in the metastatic (m) setting is poor. Programmed...

    Authors: A. Boilève, M. I. Carlo, P. Barthélémy, S. Oudard, D. Borchiellini, M. H. Voss, S. George, C. Chevreau, J. Landman-Parker, M-D Tabone, D. D. Chism, A. Amin, M. A. Bilen, D. Bosse, A. Coulomb-L’hermine, Xiaoping Su…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:159

    Published on:

  10. Content type: Research article

    PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune syste...

    Authors: Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson and Simon T. Barry

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:158

    Published on:

  11. Content type: Commentary

    Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype. Melanoma and lung cancer demon...

    Authors: Saman Maleki Vareki

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:157

    Published on:

  12. Content type: Case report

    The prevalence of esophageal stenosis caused by immune checkpoint inhibitors in the context of induced immune mucositis and esophagitis is extremely rare.

    Authors: Alice Horisberger, Stefano La Rosa, Jean-Philippe Zurcher, Stefan Zimmermann, Francois Spertini, George Coukos and Michel Obeid

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:156

    Published on:

  13. Content type: Research article

    Immune-checkpoint inhibitors plus chemotherapy are emerging as effective first-line treatment in advanced non-small-cell lung carcinoma (NSCLC), but little is known about the magnitude of benefits and potentia...

    Authors: Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:155

    Published on:

  14. Content type: Commentary

    Immune checkpoint inhibitors which activate the host’s immune system to fight cancer have brought dramatic improvements to the overall survival of a growing number of deadly malignancies. Their use comes at th...

    Authors: Khashayar Esfahani

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:154

    Published on:

  15. Content type: Case report

    Neurologic toxicities with immune therapy are rare, but can cause devastating and often permanent injury when they occur. Although there is increasing interest in the potential synergism between immune therapy...

    Authors: Victoria A. Chang, Daniel R. Simpson, Gregory A. Daniels and David E. Piccioni

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:153

    Published on:

  16. Content type: Research article

    Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the...

    Authors: Christina Jensen, Daniel Hargbøl Madsen, Morten Hansen, Henrik Schmidt, Inge Marie Svane, Morten Asser Karsdal and Nicholas Willumsen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:152

    Published on:

  17. Content type: Research article

    Tumor-associated macrophages (TAMs) facilitate tumor progression via establishment of an immunosuppressive tumor microenvironment (TME). However, it is poorly understood how tumor cells could functionally modu...

    Authors: Zhi-Fa Wen, Hongxiang Liu, Rong Gao, Meng Zhou, Jie Ma, Yue Zhang, Jinjin Zhao, Yongqiang Chen, Tianyu Zhang, Fang Huang, Ning Pan, Jinping Zhang, Bernard A. Fox, Hong-Ming Hu and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:151

    Published on:

  18. Content type: Case report

    Immune checkpoint inhibitors have revolutionized treatment and improved survival in many cancers. However, since immune-related adverse events (irAEs) are potentially fatal, early recognition and prompt treatm...

    Authors: Cecilia Monge, Hoyoung Maeng, Alessandra Brofferio, Andrea B. Apolo, Bharath Sathya, Andrew E. Arai, James L. Gulley and Marijo Bilusic

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:150

    Published on:

  19. Content type: Research article

    Simultaneous blockade of immune checkpoint molecules and co-stimulation of the TNF receptor superfamily (TNFRSF) is predicted to improve overall survival in human cancer. TNFRSF co-stimulation depends upon coo...

    Authors: George Fromm, Suresh de Silva, Kellsey Johannes, Arpita Patel, Josiah C. Hornblower and Taylor H. Schreiber

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:149

    Published on:

  20. Content type: Research article

    Tumor cell mediated immune-suppression remains a question of interest in tumor biology. In this study, we focused on the metabolites that are released by prostate cancer cells (PCC), which could potentially at...

    Authors: Yutao Yan, Lei Chang, Hongzhe Tian, Lu Wang, Yawei Zhang, Tao Yang, Guohao Li, Weifeng Hu, Kavita Shah, Gang Chen and Yonglian Guo

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:148

    Published on:

  21. Content type: Case report

    Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of ac...

    Authors: Lucas C. Adam, Junaid Raja, Johannes M. Ludwig, Adebowale Adeniran, Scott N. Gettinger and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:147

    Published on:

  22. Content type: Research article

    Ligands for the Toll-like receptor (TLR) family can induce activation of cells of the innate immune system and are widely studied for their potential to enhance adaptive immunity. Conjugation of TLR2-ligand Pa...

    Authors: Gijs G. Zom, Marian M. J. H. P. Willems, Selina Khan, Tetje C. van der Sluis, Jan Willem Kleinovink, Marcel G. M. Camps, Gijsbert A. van der Marel, Dmitri V. Filippov, Cornelis J. M. Melief and Ferry Ossendorp

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:146

    Published on:

  23. Content type: Research article

    Regulatory B (Breg) cells represent one of the B cell subsets that infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the phenotype, function and clinical re...

    Authors: Linsen Ye, Qi Zhang, Yusheng Cheng, Xiaolong Chen, Guoying Wang, Mengchen Shi, Tong Zhang, Yingjiao Cao, Hang Pan, Liting Zhang, Genshu Wang, Yinan Deng, Yang Yang and Guihua Chen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:145

    Published on:

  24. Content type: Research article

    Immunotherapy has ushered in a new era of cancer therapy, and this is also applicable to therapy of hepatocellular carcinoma (HCC). In this context, effective development of therapeutic strategies requires an ...

    Authors: Yu-Tzu Liu, Tai-Chung Tseng, Ruey-Shyang Soong, Chun-Yi Peng, Yu-Hsing Cheng, Shiu-Feng Huang, Tsung-Hsien Chuang, Jia-Horng Kao and Li-Rung Huang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:144

    Published on:

  25. Content type: Commentary

    Unlike chemotherapy treatments that target the tumor itself (rather nonspecifically), immune-based therapies attempt to harness the power of an individual patient’s immune system to combat cancer. Similar to c...

    Authors: Shanta Bantia and Nirmal Choradia

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:143

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:56

  26. Content type: Research article

    Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These...

    Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Dana Alsaadi, Joseph Jennings, Wenyi Luo, Zimu Gong, David M. Richards, Aline Charabaty and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:142

    Published on:

  27. Content type: Research article

    Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and ...

    Authors: Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:141

    Published on:

  28. Content type: Review

    Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerg...

    Authors: Junaid Raja, Johannes M. Ludwig, Scott N. Gettinger, Kurt A. Schalper and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:140

    Published on:

  29. Content type: Research article

    A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). Howev...

    Authors: Iva Truxova, Lenka Kasikova, Michal Hensler, Petr Skapa, Jan Laco, Ladislav Pecen, Lucie Belicova, Ivan Praznovec, Michael J. Halaska, Tomas Brtnicky, Eva Salkova, Lukas Rob, Roman Kodet, Jeremy Goc, Catherine Sautes-Fridman, Wolf Herman Fridman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:139

    Published on:

  30. Content type: Review

    Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomark...

    Authors: Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif and Ena Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:138

    Published on:

  31. Content type: Review

    Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with h...

    Authors: Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June and Michael R. Bishop

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:137

    Published on:

  32. Content type: Research article

    The anti-tumor immunity of natural killer (NK) cells can be paralyzed by the CD73-induced generation of immunosuppressive adenosine from precursor ATP within the hypoxic microenvironment of solid tumors. In an...

    Authors: Jiao Wang, Kyle B. Lupo, Andrea M. Chambers and Sandro Matosevic

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:136

    Published on:

  33. Content type: Commentary

    Recent randomized phase III trials (KEYNOTE-407 and IMpower131) reported that adding anti-programmed death (ligand) 1 (anti-PD-(L)1) antibodies in combination with taxane-platinum improve the therapeutic effic...

    Authors: Yaxiong Zhang, Huaqiang Zhou and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:135

    Published on:

  34. Content type: Clinical trials monitor

    AGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and therapeutic settings. We present updated long-term survival results ...

    Authors: Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki and Andrzej Mackiewicz

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:134

    Published on:

  35. Content type: Research article

    Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a ...

    Authors: Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong and James W. Hodge

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:133

    Published on:

  36. Content type: Research article

    Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specifi...

    Authors: Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:131

    Published on:

  37. Content type: Case report

    Currently, there is no established standard of care for patients with metastatic CSCC. Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.

    Authors: Leandro J. C. Oliveira, Aline B. L. Gongora, Felipe G. Barbosa, Carlos H. dos Anjos and Rodrigo R. Munhoz

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:130

    Published on:

  38. Content type: Research article

    Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lu...

    Authors: Aixa E. Soyano, Bhagirathbhai Dholaria, Julian A. Marin-Acevedo, Nancy Diehl, David Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex Adjei, Keith L. Knutson and Yanyan Lou

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:129

    Published on:

  39. Content type: Review

    Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inh...

    Authors: Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone II, Joe Y. Chang, James W. Welsh and Charles R. Thomas Jr

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:128

    Published on:

  40. Content type: Case report

    MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy. Here, we report the first case of acquired resistance to immunotherapy in MMR-D pancreatic cancer.

    Authors: Zishuo Ian Hu, Matthew D. Hellmann, Jedd D. Wolchok, Monika Vyas, Jinru Shia, Zsofia K. Stadler, Luis A. Diaz Jr and Eileen M. O’Reilly

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:127

    Published on:

  41. Content type: Case report

    Immunotherapy with immune checkpoint inhibitors has radically changed the management of a broad spectrum of tumors. In contrast, only very limited information is available about the efficacy of these therapies...

    Authors: Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone and Stefano Pepe

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:126

    Published on:

  42. Content type: Research article

    Interleukin-12 (IL-12) is a promising candidate for cancer immunotherapy because of its ability to activate a number of host immune subsets that recognize and destroy cancer cells. We found that human hepatoce...

    Authors: Ian Lai, Srividya Swaminathan, Virginie Baylot, Adriane Mosley, Renumathy Dhanasekaran, Meital Gabay and Dean W. Felsher

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:125

    Published on:

  43. Content type: Research article

    Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC). The current study aimed to ass...

    Authors: Bin Wu, Qiang Zhang and Jie Sun

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:124

    Published on:

  44. Content type: Research article

    T lymphocytes and HLA expression on tumor cell both influence prognostic of localized colorectal cancer, but their role following chemotherapy in patients with liver metastatic colorectal cancer (mCRC) was not...

    Authors: Fanny Ledys, Quentin Klopfenstein, Caroline Truntzer, Laurent Arnould, Julie Vincent, Leila Bengrine, Romain Remark, Romain Boidot, Sylvain Ladoire, Francois Ghiringhelli and Valentin Derangere

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:123

    Published on:

  45. Content type: Case report

    Immune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized,...

    Authors: David M. Miller, Ryan M. Trowbridge, Anupam Desai and Reed E. Drews

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:122

    Published on:

  46. Content type: Commentary

    Innate lymphoid cells (ILCs) are increasingly being recognized for their ability to impact both innate and adaptive immune cells in diverse contexts. ILCs have been observed in all secondary lymphoid tissues, ...

    Authors: Sarah Q. Crome and Pamela S. Ohashi

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:121

    Published on:

  47. Content type: Commentary

    Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resec...

    Authors: Thibault Comont, Vincent Sibaud, Loïc Mourey, Pierre Cougoul and Odile Beyne-Rauzy

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:120

    Published on:

Annual Journal Metrics

Advertisement